DE60128916D1 - Neues, physiologisch aktives peptid und dessen verwendung - Google Patents
Neues, physiologisch aktives peptid und dessen verwendungInfo
- Publication number
- DE60128916D1 DE60128916D1 DE60128916T DE60128916T DE60128916D1 DE 60128916 D1 DE60128916 D1 DE 60128916D1 DE 60128916 T DE60128916 T DE 60128916T DE 60128916 T DE60128916 T DE 60128916T DE 60128916 D1 DE60128916 D1 DE 60128916D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- compound
- salt
- screening
- new
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000217442 | 2000-07-18 | ||
JP2000217442 | 2000-07-18 | ||
JP2001026779 | 2001-02-02 | ||
JP2001026779 | 2001-02-02 | ||
PCT/JP2001/006162 WO2002006483A1 (fr) | 2000-07-18 | 2001-07-17 | Nouveau peptide actif sur le plan physiologique et utilisation associee |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60128916D1 true DE60128916D1 (de) | 2007-07-26 |
DE60128916T2 DE60128916T2 (de) | 2007-09-20 |
Family
ID=26596235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60128916T Expired - Lifetime DE60128916T2 (de) | 2000-07-18 | 2001-07-17 | Neues, physiologisch aktives peptid und dessen verwendung |
Country Status (6)
Country | Link |
---|---|
US (2) | US7045299B2 (de) |
EP (1) | EP1302542B1 (de) |
AT (1) | ATE364698T1 (de) |
AU (1) | AU2001272735A1 (de) |
DE (1) | DE60128916T2 (de) |
WO (1) | WO2002006483A1 (de) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223727B2 (en) * | 1998-04-09 | 2007-05-29 | Serono Genetics Institute S.A. | GSSP4 polynucleotides and polypeptides and uses thereof |
AU6728000A (en) * | 1999-08-27 | 2001-03-26 | Takeda Chemical Industries Ltd. | Novel g protein-coupled receptor protein and dna thereof |
US6485938B1 (en) | 1999-11-16 | 2002-11-26 | Zymogenetics, Inc. | Nucleic acid molecules that encodes human Zven1 |
AU2002230778A1 (en) | 2000-11-03 | 2002-05-15 | The Regents Of The University Of California | Prokineticin polypeptides, related compositions and methods |
AU2002367629A1 (en) * | 2001-02-05 | 2003-10-08 | Bristol-Myers Squibb Company | A novel human g-protein coupled receptor, hgprbmy14, related to the orphan gpcr, gpr73 |
US20050176632A1 (en) * | 2002-02-04 | 2005-08-11 | Tetsuya Ohtaki | Angiogenesis inhibitors |
US7410956B2 (en) * | 2002-02-11 | 2008-08-12 | Vertex Pharmaceuticals Incorporated | Caspase inhibitor prodrugs |
EP1572099A4 (de) | 2002-10-04 | 2007-01-03 | Univ California | Screening und therapeutische verfahren im zusammenhang mit der neurogenese |
CA2500962A1 (en) * | 2002-10-07 | 2004-04-15 | Zymogenetics, Inc. | Uses of human zven proteins and polynucleotides |
US7662380B2 (en) * | 2003-01-22 | 2010-02-16 | Takeda Pharmaceutical Company Limited | ZAQ ligand-1 antibodies and uses thereof |
WO2007033140A2 (en) * | 2005-09-13 | 2007-03-22 | Zymogenetics, Inc. | Prok2 antagonists and methods of use |
JP2007121271A (ja) * | 2005-09-30 | 2007-05-17 | National Institute Of Advanced Industrial & Technology | 8−ヒドロキシ−2’−デオキシグアノシンの測定方法及び測定のための装置 |
WO2008096905A1 (ja) | 2007-02-09 | 2008-08-14 | Tokyo Metropolitan Organization For Medical Research | 抗brak(cxcl14)ヒトモノクローナル抗体及びその用途 |
JP5504513B2 (ja) * | 2008-02-19 | 2014-05-28 | 株式会社タニタ | カラム充填剤、これを用いたカラムおよび分離方法 |
KR20150084007A (ko) | 2012-11-13 | 2015-07-21 | 리제너론 파아마슈티컬스, 인크. | 항-프로키네티신 수용체 (prokr) 항체 및 이의 용도 |
US9942187B2 (en) | 2014-03-10 | 2018-04-10 | Harry Leonard Perper | Alert for messages “stuck” in a message queue within a messaging application |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
BR112017009497A2 (pt) | 2014-11-05 | 2018-02-06 | Voyager Therapeutics, Inc. | polinucleotídeos de aadc para o tratamento da doença de parkinson |
RU2020108189A (ru) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | Композиции и способы лечения бокового амиотрофического склероза (als) |
CN112410338A (zh) | 2014-11-14 | 2021-02-26 | 沃雅戈治疗公司 | 调节性多核苷酸 |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
EP3448987A4 (de) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
KR20240056729A (ko) | 2016-05-18 | 2024-04-30 | 보이저 테라퓨틱스, 인크. | 조절성 폴리뉴클레오티드 |
CA3024449A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
RU2662944C1 (ru) * | 2017-02-17 | 2018-07-31 | Общество с ограниченной ответственностью "Группа развития "АПЕКС" | Средство для лечения состояний человеческого организма, связанных с уменьшением уровня экспрессии гена prok 1 и/или уменьшением количества белка прокинетицина 1 на основе генно-терапевтических субстанций с геном prok 1, способ получения и использования |
CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
MX2019013172A (es) | 2017-05-05 | 2020-09-07 | Voyager Therapeutics Inc | Composiciones y metodos para tratar la enfermedad de huntington. |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CA3070087A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | Trajectory array guide system |
TWI832036B (zh) | 2017-08-03 | 2024-02-11 | 美商航海家醫療公司 | 用於aav之遞送之組合物及方法 |
TWI804518B (zh) | 2017-10-16 | 2023-06-11 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
WO2019173434A1 (en) | 2018-03-06 | 2019-09-12 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
EP3793615A2 (de) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Gerichtete entwicklung von aav zur verbesserung des tropismus für zns |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
AU2019299861A1 (en) | 2018-07-02 | 2021-01-14 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
WO2020023612A1 (en) | 2018-07-24 | 2020-01-30 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
EP3861113A1 (de) | 2018-10-04 | 2021-08-11 | Voyager Therapeutics, Inc. | Verfahren zur messung des titers und der potenz von viralen vektorpartikeln |
MX2021008542A (es) | 2019-01-18 | 2021-11-12 | Voyager Therapeutics Inc | Métodos y sistemas para la producción de partículas de aav. |
EP3962536A1 (de) | 2019-04-29 | 2022-03-09 | Voyager Therapeutics, Inc. | Systeme und verfahren zur herstellung von baculovirusinfizierten insektenzellen (biics) in bioreaktoren |
WO2021030125A1 (en) | 2019-08-09 | 2021-02-18 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20220364114A1 (en) | 2019-08-26 | 2022-11-17 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20230295656A1 (en) | 2020-08-06 | 2023-09-21 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20240141377A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000053753A2 (en) * | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
US5891720A (en) * | 1997-04-17 | 1999-04-06 | Millennium Pharmaceuticals, Inc. | Isolated DNA encoding a novel human G-protein coupled receptor |
CA2296287A1 (en) | 1997-08-01 | 1999-02-11 | Genset | 5' ests for secreted proteins expressed in prostate |
CA2328895A1 (en) * | 1998-06-02 | 1999-12-09 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU2172300A (en) | 1998-12-10 | 2000-06-26 | Synaptic Pharmaceutical Corporation | Dna encoding a mammalian receptor (fb41a) and uses thereof |
CA2362924A1 (en) * | 1999-03-01 | 2000-09-08 | Millennium Pharmaceuticals, Inc. | Secreted proteins and nucleic acids encoding them |
JP2002543840A (ja) * | 1999-05-19 | 2002-12-24 | インサイト・ゲノミックス・インコーポレイテッド | 細胞外シグナル伝達分子 |
CA2383254A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
AU3246100A (en) * | 1999-06-02 | 2000-12-28 | Genentech Inc. | Methods and compositions for inhibiting neoplastic cell growth |
AU6728000A (en) * | 1999-08-27 | 2001-03-26 | Takeda Chemical Industries Ltd. | Novel g protein-coupled receptor protein and dna thereof |
EP1230362A2 (de) | 1999-11-16 | 2002-08-14 | ZymoGenetics, Inc. | Menschliche zven proteine |
-
2001
- 2001-07-17 AU AU2001272735A patent/AU2001272735A1/en not_active Abandoned
- 2001-07-17 US US10/333,192 patent/US7045299B2/en not_active Expired - Fee Related
- 2001-07-17 DE DE60128916T patent/DE60128916T2/de not_active Expired - Lifetime
- 2001-07-17 EP EP01951893A patent/EP1302542B1/de not_active Expired - Lifetime
- 2001-07-17 WO PCT/JP2001/006162 patent/WO2002006483A1/ja active IP Right Grant
- 2001-07-17 AT AT01951893T patent/ATE364698T1/de not_active IP Right Cessation
-
2005
- 2005-12-15 US US11/304,129 patent/US7419956B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE364698T1 (de) | 2007-07-15 |
EP1302542A4 (de) | 2005-05-11 |
EP1302542B1 (de) | 2007-06-13 |
AU2001272735A1 (en) | 2002-01-30 |
WO2002006483A1 (fr) | 2002-01-24 |
US7419956B2 (en) | 2008-09-02 |
US20060088915A1 (en) | 2006-04-27 |
US20040077535A1 (en) | 2004-04-22 |
EP1302542A1 (de) | 2003-04-16 |
DE60128916T2 (de) | 2007-09-20 |
US7045299B2 (en) | 2006-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE364698T1 (de) | Neues, physiologisch aktives peptid und dessen verwendung | |
DE60311272D1 (de) | Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten | |
CY1114679T1 (el) | Συνθεσεις για διαγνωση και θεραπεια ασθενειων που συνδυαζονται με παρεκκλινουσα εκφραση φουτρινων (r-σπονδινων) | |
DE60311820D1 (de) | Neue verwendung von pyrimidin- oder triazin-2-carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2-carbonsäurenitrilderivate | |
WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
ATE411805T1 (de) | Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen | |
EA200601212A1 (ru) | Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение | |
ATE439833T1 (de) | Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten | |
EP1978362A3 (de) | Cross-Beta-Struktur mit Amyloid-bindenden Proteinen und Verfahren für den Nachweis einer Cross-Beta-Struktur, zur Modulation der Fibrillenbildung von Cross-Beta-Strukturen und Cross-Beta-Struktur-vermittelter Toxizität | |
ATE209684T1 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
EA200501711A1 (ru) | Семейство секретируемых белков | |
DE50212280D1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
DE60107888D1 (de) | Beta-Interferon zur Behandlung von Immunerkrankungen | |
IL169256A (en) | Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it | |
NO20034269L (no) | Anvendelse av forbindelser med den biologiske aktivitet til vaskoaktivt intestinalt peptid for behandlingen av kronisk obstruktiv pulmonalsykdom | |
DE60311822D1 (de) | Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen | |
WO2002062944A3 (fr) | Nouveau peptide physiologiquement actif et son utilisation | |
WO2002007676A3 (en) | Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr) | |
NO20052525L (no) | Spleisevariant av humant hypofyseveksthormon | |
DE10394363D2 (de) | Neue Chelidonin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen | |
ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
EA200501843A1 (ru) | Tnf-подобный секретируемый белок | |
WO2003064646A1 (fr) | Nouveau peptide et son utilisation | |
EA200501679A2 (ru) | Фосфонатсодержащие противовоспалительные соединения (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ подавления воспалительной активности (варианты) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |